Cover Image
Market Research Report

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 934858
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024
Published: May 2, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the parp (Poly ADP-ribose Polymerase) inhibitors market and it is poised to grow by $ 810.23 million during 2020-2024 progressing at a CAGR of 12% during the forecast period. Our reports on parp (Poly ADP-ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the expanded application of PARP inhibitors and increasing patient assistance programs. In addition, expanded application of PARP inhibitors is anticipated to boost the growth of the market as well.

The parp (Poly ADP-ribose Polymerase) inhibitors market analysis includes end-user segment and geographic landscapes

Technavio's ‘ parp (Poly ADP-ribose Polymerase) inhibitors market ’ is segmented as below:

By End-User

  • Ovarian cancer
  • Breast cancer
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • APAC
  • South America
  • MEA

This study identifies the ease of administration as one of the prime reasons driving the parp (Poly ADP-ribose Polymerase) inhibitors market growth during the next few years.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our parp (Poly ADP-ribose Polymerase) inhibitors market covers the following areas:

  • Parp (Poly ADP-ribose Polymerase) inhibitors market sizing
  • Parp (Poly ADP-ribose Polymerase) inhibitors market forecast
  • Parp (Poly ADP-ribose Polymerase) inhibitors market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-ribose Polymerase) inhibitors market vendors that include AbbVie Inc., AstraZeneca Plc, Bayer AG, Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the parp (Poly ADP-ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR43323

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market size 2019
  • Market segment analysis
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by End-user

  • Market segments
  • Comparison by End-user
  • Ovarian cancer - Market size and forecast 2019-2024
  • Breast cancer - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by End user

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor Landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: End user - Market share 2019-2024 (%)
  • 22: Comparison by End user
  • 23: Ovarian cancer - Market size and forecast 2019-2024 ($ million)
  • 24: Ovarian cancer - Year-over-year growth 2019-2024 (%)
  • 25: Breast cancer - Market size and forecast 2019-2024 ($ million)
  • 26: Breast cancer - Year-over-year growth 2019-2024 (%)
  • 27: Others - Market size and forecast 2019-2024 ($ million)
  • 28: Others - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by End user
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: South America - Market size and forecast 2019-2024 ($ million)
  • 40: South America - Year-over-year growth 2019-2024 (%)
  • 41: MEA - Market size and forecast 2019-2024 ($ million)
  • 42: MEA - Year-over-year growth 2019-2024 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: AbbVie Inc. - Overview
  • 52: AbbVie Inc. - Business segments
  • 53: AbbVie Inc. - Key offerings
  • 54: AbbVie Inc. - Key customers
  • 55: AbbVie Inc. - Segment focus
  • 56: AstraZeneca Plc - Overview
  • 57: AstraZeneca Plc - Business segments
  • 58: AstraZeneca Plc - Key offerings
  • 59: AstraZeneca Plc - Key customers
  • 60: AstraZeneca Plc - Segment focus
  • 61: Bayer AG - Overview
  • 62: Bayer AG - Business segments
  • 63: Bayer AG - Key offerings
  • 64: Bayer AG - Key customers
  • 65: Bayer AG - Segment focus
  • 66: Clovis Oncology Inc. - Overview
  • 67: Clovis Oncology Inc. - Business segments
  • 68: Clovis Oncology Inc. - Key offerings
  • 69: Clovis Oncology Inc. - Key customers
  • 70: Clovis Oncology Inc. - Segment focus
  • 71: Daiichi Sankyo Co. Ltd. - Overview
  • 72: Daiichi Sankyo Co. Ltd. - Business segments
  • 73: Daiichi Sankyo Co. Ltd. - Key offerings
  • 74: Daiichi Sankyo Co. Ltd. - Key customers
  • 75: Daiichi Sankyo Co. Ltd. - Segment focus
  • 76: GlaxoSmithKline Plc - Overview
  • 77: GlaxoSmithKline Plc - Business segments
  • 78: GlaxoSmithKline Plc - Key offerings
  • 79: GlaxoSmithKline Plc - Key customers
  • 80: GlaxoSmithKline Plc - Segment focus
  • 81: Jiangsu Hengrui Medicine Co. Ltd. - Overview
  • 82: Jiangsu Hengrui Medicine Co. Ltd. - Business segments
  • 83: Jiangsu Hengrui Medicine Co. Ltd. - Key offerings
  • 84: Jiangsu Hengrui Medicine Co. Ltd. - Key customers
  • 85: Jiangsu Hengrui Medicine Co. Ltd. - Segment focus
  • 86: Johnson & Johnson - Overview
  • 87: Johnson & Johnson - Business segments
  • 88: Johnson & Johnson - Key offerings
  • 89: Johnson & Johnson - Key customers
  • 90: Johnson & Johnson - Segment focus
  • 91: Pfizer Inc. - Overview
  • 92: Pfizer Inc. - Business segments
  • 93: Pfizer Inc. - Key offerings
  • 94: Pfizer Inc. - Key customers
  • 95: Pfizer Inc. - Segment focus
  • 96: Teva Pharmaceutical Industries Ltd. - Overview
  • 97: Teva Pharmaceutical Industries Ltd. - Business segments
  • 98: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 99: Teva Pharmaceutical Industries Ltd. - Key customers
  • 100: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations
Back to Top